Inari Medical (NASDAQ:NARI) Rating Lowered to Neutral at Piper Sandler

Piper Sandler downgraded shares of Inari Medical (NASDAQ:NARI – Free Report) from an overweight rating to a neutral rating in a report published on Thursday morning, MarketBeat.com reports. Piper Sandler currently has $55.00 target price on the stock, down from their prior target price of $85.00. Other equities research analysts also recently issued reports about […]

Leave a Reply

Your email address will not be published.

Previous post FIGS (NYSE:FIGS) Downgraded to Market Perform at Telsey Advisory Group
Next post Are the Chicago White Sox eyeing a stadium move to the South Loop?